Irinocan (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cancer cells to SN‑38, an active metabolite that inhibits topoisomerase I. This inhibition prevents the re‑ligation of single‑strand DNA breaks during replication, leading to DNA damage, cell‑cycle arrest and ultimately tumor cell death.

The dosing regimen for Irinocan is individualized by the prescribing oncologist based on factors such as patient weight, performance status, prior therapies and laboratory values. The prescriber determines the appropriate dose, schedule and any necessary dose adjustments.

Safety data for Irinocan in pregnancy and lactation are limited, and the drug may pose risks to the fetus or nursing infant. It is generally contraindicated in pregnant or breastfeeding women unless the potential benefit justifies the potential risk, and a specialist should be consulted.

To request Irinocan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinocan belongs to the topoisomerase I inhibitor class, whereas alternatives such as oxaliplatin or fluoropyrimidines act on DNA cross‑linking or thymidylate synthase, respectively. Irinocan offers a distinct mechanism that can be synergistic when combined with these agents, but its toxicity profile, especially for neutropenia and diarrhea, differs and requires specific monitoring.

Irinocan should be stored at ambient temperature, protected from moisture and light, and kept in its original packaging until use. Once reconstituted for intravenous infusion, it must be used within the time frame specified in the product labeling and discarded if any discoloration or particulate matter is observed.

Irinocan is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30 to 90 minutes, depending on the prescribed protocol and patient tolerance. Infusion rates and pre‑medication for anti‑emesis are determined by the treating physician.

The most serious adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, allergic reactions such as anaphylaxis, and hepatic toxicity. Prompt recognition and supportive care are essential, and patients should be educated to report fever, persistent diarrhea, or signs of infection immediately.

Irinocan is contraindicated in patients with known hypersensitivity to Irinotecan or any of its excipients, in those with severe bone‑marrow suppression, and in individuals receiving concurrent strong CYP3A4 or UGT1A1 inhibitors that cannot be safely managed. Clinicians must assess each patient’s medical history before initiating therapy.